KR102232817B1 - Pharmaceutical composition for preventing or treating cancer, comprising a Senecio Rowleyanus Jacobs extract - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising a Senecio rowleyanus Jacobs extract and a health functional food for preventing or alleviating cancer. By using the pharmaceutical composition for preventing or treating cancer comprising a Senecio rowleyanus Jacobs extract according to the present invention as an active ingredient, and a health functional food composition for preventing or alleviating cancer comprising a Senecio rowleyanus Jacobs extract as an active ingredient, it is possible to specifically inhibit proliferation of cancer cells with less side effects, exhibiting antioxidant activity and regulating the expression of cancer cell death-related genes by suppressing a citric acid cycle, so as to effectively prevent or treat cancer, and thus can be widely used in the pharmaceutical industry and health functional food fields.

Description

Pharmaceutical composition for preventing or treating cancer, comprising a Senecio Rowleyanus Jacobs extract}

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a green younggeum extract, and to a health functional food for preventing or improving cancer.

Demand for physiologically active substances and medicinal plants is rapidly increasing in various bio-industry fields such as health functional foods, functional cosmetics, and pharmaceuticals, and the stability of imports of functional raw materials from abroad is decreasing due to global trade manufacturing measures. In addition, the trend of people's preference for domestically developed materials is reinforcing, and the demand and importance of developing raw materials are increasing rapidly both globally and emotionally. On the other hand, the number of newly recognized functional ingredients for the development of health functional foods in Korea has continued to decline since 95 cases in 2009, to only 9 cases in 2018, and the development of functional ingredients is very urgent.

Green Younggeum (Senecio Rowleyanus Jacobs) is a succulent plant in the Asteraceae family, with round pea-shaped leaves hanging from the stem and hitting the soil to grow. In general, in Korea, they are called nokyeonggeum or nokyoung, beannan, and bean cactus, and in the United States, the names string-of-pearls and string-of-beads are used. With such a peculiar appearance, Nokyeonggeum is cultivated as an ornamental plant, and no deep research has been done on physiological activity, and no related patent has been filed in Korea. Overseas, it has been reported to be mildly toxic, such as vomiting and diarrhea when ingesting stems (Filmer, A. K., & Dodge, L. (2012). Safe and Poisonous Garden Plants. University of California, Davis. USA.). Plant extracts are recognized as safe compared to chemical components, but excessive doses of plant extracts can cause serious toxicity to the human body. Recently, in Jeju Island, the death of an elderly person who ingested the Gaksi Phu Guo flower, which was also used as a raw material for medicine during the Joseon Dynasty, was reported to be effective in rejuvenation, arthritis, stroke, and diabetes when taking very small amounts in oriental medicine. . As such, cases in which poisonous plants have useful physiological activities in the human body are increasing, and in the present invention, studies on anticancer compositions were conducted using green younggeum, which is known to be slightly toxic.

According to the National Statistical Office, the number 1 cause of death for Koreans as of 2017 was "cancer", accounting for 27.6%, and according to the National Cancer Information Center, the incidence of cancer was 35.3%, which is 1 in 3 people if they survive until the age of 82 as of 2015. Become self. Korean men had the highest incidence of gastric cancer, lung cancer, colon cancer, liver cancer, and prostate cancer, and women had the highest incidence of thyroid cancer, breast cancer, colon cancer, stomach cancer, and lung cancer, while skin cancer accounted for a relatively small percentage. However, with the recent global climate change, the risk of skin cancer is increasing rapidly. According to the Health Insurance Review and Assessment Service, the number of domestic skin cancer treatments increased from 17,455 in 2015 to 21,187 in 2017, an increase of 21.4%. Among skin cancers, malignant melanoma is caused by mutations in melanocytes, and genetic factors and environmental factors such as increased exposure to UV rays are the main causes, and the recent increase in fine dust may also be the cause of skin cancer. However, research in Korea is still insufficient compared to gastric cancer and lung cancer. Melanoma is a cancer composed of melanocytes and is divided into benign melanoma and malignant melanoma. It mainly occurs in the skin exposed to UV rays, but can also occur in the eyes and various organs where melanogenic cells are present. Malignant melanoma mainly develops more frequently in people with light skin color due to low melanin production, and it is congenital and acquired. According to data from the National Cancer Center and Health Insurance Review and Assessment Service, although the incidence of skin cancer is lower in Korea than in the West, the trend has continued to increase over the past five years. Melanoma is the most malignant carcinoma among skin cancers. It occurs mainly in the arms and legs, and can spread to bones and other organs. Although the tumor is mostly completely resected, it is difficult to manage due to the high likelihood of recurrence after exposure to UV rays. Therefore, there is a high demand for substances that inhibit metastasis and recurrence of melanoma, and fundamentally, it is necessary to develop a method to prevent melanoma.

Therefore, there is a need for research on an effective cancer treatment substance without side effects by producing from natural functional raw materials that exist naturally.

Thus, the inventors of the present invention were researching substances for cancer treatment using natural substances, and the extract of Nogyeonggeum specifically inhibits the proliferation of cancer cells, exhibits antioxidant activity, and inhibits the citric acid cycle to regulate the expression of genes related to cancer cell death. By confirming that, the present invention was completed.

Therefore, it is an object of the present invention to provide a pharmaceutical composition for preventing or treating cancer comprising a green younggeum extract.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating cancer comprising an extract of Senecio Rowleyanus Jacob as an active ingredient.

In addition, the present invention provides a health functional food composition for preventing or improving cancer comprising an extract of Nokyeonggeum (Senecio Rowleyanus Jacob) as an active ingredient.

When using a pharmaceutical composition for preventing or treating cancer comprising the extract of Nogyeonggeum according to the present invention as an active ingredient, and a health functional food composition for preventing or improving cancer comprising the extract of Nogyeonggeum as an active ingredient, there are few side effects and specific for cancer cells. It can effectively prevent or treat cancer by inhibiting proliferation, exhibiting antioxidant activity, and regulating the expression of cancer cell death-related genes by inhibiting the citric acid cycle, and thus can be widely used in the pharmaceutical industry and health functional food field.

1 is a diagram illustrating the cell survival rate when the B16F10 melanoma cells and NIH/3T3 fibroblasts were treated with a green younggeum extract for 24 hours. (A: Survival rate of B16F10 cells. B: Survival rate of NIH/3T3 cells. RSJ: Nogyeonggeum extract) (* p value <0.05, ** p value <0.01, *** p value <0.001)
FIG. 2 is a diagram illustrating cell growth (proliferation rate) for 3 days after treatment with green younggeum extract on B16F10 cells and NIH/3T3 cells. (A: Growth curve of B16F10 cells. B: Growth curve of NIH/3T3 cells. RSJ: Nogyeonggeum extract) (* p value <0.05, ** p value <0.01, *** p value <0.001)
Figure 3 is a diagram confirming the antioxidant efficacy when the green younggeum extract was treated in B16F10 cells for 24 hours. (A, B: change in the amount of reactive oxygen species produced in the cells of B16F10 cells. RSJ: Nogyeonggeum extract) (* p value <0.05, ** p value <0.01, *** p value <0.001)
4 is a diagram illustrating changes in the expression of mRNA associated with citric acid cycle and apoptosis when green younggeum extract is treated with B16F10 cells. (A: Citric acid cycle-related gene expression change. B: Apoptosis-related gene expression change. RSJ: Nogyeonggeum extract) (* p value <0.05, ** p value <0.01, *** p value <0.001)

The present invention provides a pharmaceutical composition for preventing or treating cancer comprising an extract of Nokyeonggeum (Senecio Rowleyanus Jacob) as an active ingredient.

In the present invention, the green younggeum is a perennial succulent plant of the Asteraceae family. Its origin is Africa, and it has the characteristic of growing in the shade that can avoid direct sunlight.

In the present invention, the extraction target of the nogyeonggeum extract may be one or more selected from the group consisting of leaves, stems, and roots of nogyeonggeum, and preferably may be a leaf of nogyeonggeum.

In the present invention, the Nokyounggeum extract is the extraction target water, methanol, ethanol, propanol, isopropanol, C ₁ -C ₄ alcohol such as butanol, methylene chloride, ethylene, acetone, hexane, ether, chloroform, Extract obtained by leaching using ethyl acetate, butyl acetate, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol or a mixed solvent thereof, carbon dioxide, pentane It refers to an extract obtained using a supercritical extraction solvent such as, or a fraction obtained by fractionating the extract, and the extraction method is cold sedimentation, reflux, warming, ultrasonic spinning, supercritical extraction in consideration of the polarity, extraction degree, and preservation degree of the active substance. Etc. Any method can be applied. In the case of a fractionated extract, a fraction obtained by suspending the extract in a specific solvent and mixing and policing with a solvent having a different polarity, and adsorbing the extract on a column filled with silica gel, etc., and then adding a hydrophobic solvent, a hydrophilic solvent, or a mixed solvent thereof. It means including the fraction obtained as a mobile phase. In addition, the meaning of the extract includes a concentrated liquid extract or a solid extract from which the extraction solvent has been removed by a method such as freeze drying, vacuum drying, hot air drying, spray drying, or the like. Preferably, it may be an extract obtained using water as an extraction solvent, and more preferably, it may be extracted under conditions of ^{100 to 120°C and 0.3 to 0.5Kg/cm 3 using water as a solvent.}

In the present invention, the nokyounggeum extract may be extracted by mixing 120ml of distilled water per 40g of nokyounggeum leaves, and preferably, the extract obtained by mixing 120ml of distilled water per 40g of nokyounggeum leaves is ^{diluted 10 -9} to 10 ^-5 times. When treated with cancer cells, it may be to effectively inhibit cancer cells, and more preferably, when 10 ^-7 to 10 ^-5 times dilution is applied to cancer cells, cancer cells may be effectively suppressed.

In the present invention, the green younggeum extract may be one that selectively exhibits a proliferation inhibitory effect on cancer cells, and may not be one that does not show toxicity to normal cells.

In the present invention, the Nokyounggeum extract may exhibit antioxidant activity, and based on the antioxidant activity, it reduces the level of reactive oxygen species required for the growth of cancer cells and inhibits proliferation and energy metabolism, thereby inhibiting the growth of cancer cells. I can. Therefore, the green younggeum extract of the present invention may be a cancer treatment based on antioxidant activity.

In the present invention, the green younggeum extract may inhibit the citric acid cycle in cancer cells, preferably IDH3 (Isocitrate dehydrogenase regulatory subunit 3), SUCLG1 (Succinate--CoA ligase subunit alpha), which regulates the citric acid cycle in cancer cells. And MDH1 (Malate Dehydrogenase 1) may be to suppress the expression of one or more genes selected from the group consisting of genes.

In the present invention, the nokyeonggeum extract may be treated on cancer cells to increase the expression of apoptosis genes, and preferably, may be to increase the expression of the BCL2-associated X protein gene (BAX) gene.

In the present invention, the nokyeonggeum extract may be treated to cancer cells to reduce the expression of a cell death inhibitory gene, preferably to reduce the expression of the BCL2 (B-cell lymphoma 2) gene.

In the present invention, the green younggeum extract may be one that inhibits the citric acid cycle, inhibits the growth of cancer cells, and as a result exhibits an anticancer effect through a mechanism that induces cell death.

In the present invention, the cancer is squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, skin cancer, melanoma, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine adenocarcinoma , Parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumor, breast cancer, colon cancer, colon cancer , Endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, and may be one or more selected from the group consisting of head and neck cancer, preferably melanoma.

The pharmaceutical compositions of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. have. Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oils. When formulated, it is prepared by using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, sucrose, or It is prepared by mixing lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, fragrances, and preservatives may be included. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.

The dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber. Dosage determination based on these factors is within the level of one of skill in the art, and dosages generally range from 0.01 mg/kg/day to approximately 2000 mg/kg/day. A more preferred dosage is from 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be divided several times. The above dosage does not limit the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered to mammals such as mice, livestock, and humans by various routes. All modes of administration can be expected and can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injection. Since the compound of the present invention has almost no toxicity and side effects, it is a drug that can be safely used even when taken for a long time for prophylactic purposes.

In the present invention, in addition to the active ingredient, the pharmaceutical composition for preventing or treating cancer may additionally contain any compound or natural extract that has already been verified for safety and is known to have anticancer activity in order to increase and reinforce the anticancer effect. have.

In addition, the present invention provides a health functional food composition for preventing or improving cancer comprising an extract of Nokyeonggeum (Senecio Rowleyanus Jacob) as an active ingredient.

Since the health functional food composition for preventing or improving cancer of the present invention has the same active ingredient and effect of the pharmaceutical composition for preventing or treating cancer, the contents in common between the two are described in order to avoid excessive complexity of the present specification. Is omitted.

The health functional food of the present invention includes ingredients that are commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when prepared as a drink, a flavoring agent or natural carbohydrate may be included as an additional ingredient in addition to the green younggeum extract as an active ingredient. For example, natural carbohydrates are monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrin, cyclodextrin, etc.), and Sugar alcohols (eg, xylitol, sorbitol, erythritol, etc.). As the flavoring agent, natural flavoring agents (eg, taumarin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) can be used.

The health functional food of the present invention includes forms such as tablets, capsules, pills or liquids, and foods to which the extract of the present invention can be added include, for example, various drinks, meats, sausages, bread, candy, There are snacks, noodles, ice cream, dairy products, soups, ion drinks, beverages, alcoholic beverages, gum, tea and vitamin complexes.

Terms that are not otherwise defined in the present specification have the meanings commonly used in the technical field to which the present invention pertains.

Hereinafter, the present invention will be described in detail by examples. However, the following examples are merely illustrative of the present invention, and the contents of the present invention are not limited by the following examples.

Example 1. Experimental materials and methods

1.1 Preparation of green younggeum extract

Rin 40 g of leaves of live green young-geum (Senecio Rowleyanus Jacobs; RSJ) once with distilled water, mix with 120 mL of distilled water, and mix with 120 mL of distilled water at 110°C, 0.4 kg/cm ³ under high temperature and high pressure (Wiseclave WAC-60, Daihan Scientific, Wonju-si , Gangwon-do, Korea) was extracted for 15 minutes. The aqueous solution was recovered from the extract, frozen at -80°C for 12 hours, thawed, and filtered through a 0.2 μm syringe filter (Minisart, Sartorius, Goettingen, Germany).

1.2 Cell culture conditions

NIH/3T3 fibroblasts and B16F10 melanoma cells were cultured in a CO ₂ incubator (Thermo Fisher Scientific; 95% air and 5% CO ₂ ) at 36.5°C. The culture medium was Dulbecco's modified eagle's medium (DMEM; 4.5 g/v) supplemented with 10% (v/v) fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and 1% (v/v) penicillin-streptomycin. L glucose; Corning, Corning, NY) was used.

1.3 Statistical Analysis

Each experiment was repeated at least 3 times, and the data were expressed as mean ± standard error of the mean (SD), n=3. Analysis was performed using GraphPad PRISM Version 8.0.1 (GraphPad Software, San Diego, CA) and Microsoft Excel 2019 (Microsoft, Redmond, WA). Two-tailed Student's t-test was used to calculate the p value compared to the control (vehicle).If the p value was less than 0.05, it was considered to have statistical significance, and if the p value was less than 0.05 *, less than 0.01 was **, less than 0.001 are indicated by ***.

Example 2. Confirmation of the inhibitory effect on cancer cell proliferation of Nogyeonggeum extract

An experiment was conducted to confirm the effect of the extract of Nogyeonggeum on the inhibition of cancer cell proliferation. ^{Specifically, 1×10 3} cells of B16F10 cells and NIH/3T3 cells were added to each well in a 96-well cell culture plate, and cultured for 12 hours, and then the green younggeum extract prepared in Example 1.1 was added to 1/1,000,000 of the amount of the medium ( 10 ^-6 ), 1/100,000,000 (10 ^-8 ), 1/10,000,000,000 (10 ^-10 ) were treated to be diluted in increments. After 24 hours, add 10% of the medium amount of WST-8 cell viability assay reagent (Biomax, Seoul, Korea), incubate for 2 hours, and use a microplate reader (FilterMax F3; Molecular Devices, San Jose, CA, USA) to 450 nm. The absorbance was measured, and the results are shown in FIGS. 1 and 2.

As shown in Fig. 1, when the green younggeum extract of the present invention was treated for 24 hours, the survival rate of B16F10 melanoma cells decreased in a concentration-dependent manner, and ^{the highest activity was shown at a concentration of 10 -6} , and the survival rate was 14.32± compared to the control (vehicle) It was confirmed that it decreased by 3.37%. On the other hand, in the case of NIH/3T3 cells other than cancer cells, it was confirmed that the extract of Nogyeonggeum did not affect the survival rate of the cells.

As shown in FIG. 2, it was confirmed that cell proliferation was inhibited by 29.01±2.83% compared to the control group by 72 hours treatment of ^{B16F10 melanoma cells at a concentration of 10 -6, but the proliferation of NIH/3T3 cells was not inhibited under the same conditions.} It was confirmed that it was not.

In this example, it was confirmed that the green young-geum extract did not adversely affect the survival rate and proliferation even when administered for a long period of time to normal skin cells other than cancer cells, and was not toxic, and in the cancer cells, the green young-geum extract was confirmed to have the survival rate and proliferation of cancer cells. By inhibiting, it was verified that there is a cancer prevention and treatment effect.

Example 3. Confirmation of the antioxidant effect of Nogyeonggeum extract

An experiment was conducted to confirm the potential as an anticancer treatment based on the antioxidant effect of Nogyeonggeum extract. ^{After 10 5 of} 60mm cell cultured B16F10 cells were added and cultured for 12 hours, the green younggeum extract prepared in Example 1.1 was treated at concentrations ^{of 10 -6} , 10 ^-8 , and 10 ^-10. After 24 hours, fluorogenic dichlorofluorescein diacetate (H ₂ DCFDA; Sigma-Aldrich) was treated for each culture dish at a final concentration of 10 μM. After incubation for 30 minutes, the cells were washed once with phosphate buffered saline (PBS; pH 7.4), and the change in fluorescence intensity due to reactive oxygen species was confirmed by flow cytometry (Guava EasyCyte; Millipore, Temecula, CA). DCF-Median fluorescence intensity (MFI) was calculated by FlowJo Version 10.5.3 (TreeStar, Ashland, OR), and the results are shown in FIG. 3.

As shown in Figure 3, when the green younggeum extract of the present invention was treated on B16F10 melanoma cells for 24 hours, the amount of reactive oxygen species in the cells was reduced by up to 32.79±7.09% compared to the control, confirming that there was an antioxidant effect.

Antioxidant-based cancer treatment is currently being accepted as a new concept. While conventional anticancer drugs based on induction of oxidative stress have the potential to adversely affect normal cells around cancer tissues, anticancer drugs based on antioxidants lower the level of reactive oxygen species required for rapid growth of cancer cells and inhibit proliferation and energy metabolism. Thus, cancer growth can be inhibited (Glasauer, A., & Chandel, NS (2014). Targeting antioxidants for cancer therapy. Biochemical pharmacology, 92(1), 90-101.). In this example, it was confirmed that the anti-oxidant effect of the extract of Nogyeonggeum on cancer cells was confirmed, and it was confirmed that it can act as an antioxidant-based anticancer agent.

Example 4. Confirmation of Induction of Cancer Cell Death and Inhibition Effect of Energy Metabolism of Nogyeonggeum Extract

An experiment was conducted to confirm the effect of the extract of Nogyeonggeum on the expression of apoptosis gene in cancer cells and the expression of genes related to energy metabolism. ^{Specifically, 10 6} B16F10 cells were put in a 100 mm cell culture dish and cultured for 12 hours, and then the green younggeum extract prepared in Example 1.1 was treated at a concentration ^{of 10 -6.} After 12 hours, total RNA was isolated with TRIzol Reagent (Thermo Fisher Scientific), and cDNA was synthesized with the M-MLV-RT cDNA synthesis kit (Wizbiosolutions, Seongnam, Korea). And in a 96-well optical-plate (Applied Biosystems, Foster City, CA, USA), 5μL 2×Real-Time PCR Master Mix including SYBR green (Biofact, Yuseong-gu, Daejeon, Korea), 3μL distilled water, 10ng cDNA, final 1pM primer was added to prepare a qPCR mixture. qPCR was performed under the conditions of pre-denaturing (95°C, 10 minutes) and amplification 50 cycles (15 seconds at 95°C and 1 minute at 60°C) using the StepOnePlus Real-Time PCR System (Applied Biosystems). The change in the expression of mRNA ^{was confirmed by the 2 -ΔΔCt} method and is shown in FIG. 4. The sequences of the primers used are shown in Table 1.

[Table 1]

As shown in FIG. 4, the extract of Nogyeonggeum inhibits the expression of IDH3, SUCLG1, MDH1 mRNA, which regulates the citric acid cycle in B16F10 melanoma cells, increases the expression of BAX mRNA, which induces apoptosis, and inhibits apoptosis. It was confirmed to reduce the expression of BCL2. The citric acid cycle is the metabolic mechanism that produces the most energy in cells, and cancer cells have high levels of energy metabolism to maintain rapid proliferation (Bucay, AH (2007). The biological significance of cancer: Mitochondria as a cause of cancer) and the inhibition of glycolysis with citrate as a cancer treatment.Medical hypotheses, 69(4), 826-828.).

In this example, it was confirmed that the green younggeum extract inhibits the citric acid cycle, thereby inducing the inhibition of the growth of melanoma cells, and as a result, the expression of BAX mRNA, which induces apoptosis, is increased. Therefore, it was confirmed that the green younggeum extract exhibits anticancer effect.

As described above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, it is obvious that these specific techniques are only preferred embodiments, and the scope of the present invention is not limited thereby. something to do. Therefore, it will be said that the practical scope of the present invention is defined by the appended claims and their equivalents.

Hereinafter, examples of the preparation of a pharmaceutical composition for preventing or treating cancer or a health functional food composition comprising the extract of Nogyeonggeum of the present invention are described, but are not intended to limit the present invention, but only to describe it in detail.

Formulation Example 1. Preparation of powder

100 mg of green young-geum extract of the present invention

1 g lactose

The above ingredients were mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2. Preparation of tablets

100 mg of green younggeum extract of the present invention

Corn starch 100 mg

100 mg lactose

2 mg of magnesium stearate

After mixing the above ingredients, tablets were prepared by tableting according to a conventional tablet preparation method.

Formulation Example 3. Preparation of Capsule

100 mg of green younggeum extract of the present invention

Corn starch 100 mg

100 mg lactose

2 mg of magnesium stearate

After mixing the above ingredients, a gelatin capsule was filled according to a conventional capsule preparation method to prepare a capsule formulation.

Formulation Example 4. Preparation of Pill

100 mg of green younggeum extract of the present invention

1.5 g lactose

1 g glycerin

0.5 g xylitol

After mixing the above components, it was prepared so as to be 4 g per ring according to a conventional method.

Formulation Example 5. Preparation of granules

100 mg of green younggeum extract of the present invention

Soybean extract 50 mg

200 mg of glucose

Starch 600 mg

After mixing the above ingredients, 100 mg of 30% ethanol was added, dried at 60°C to form granules, and then filled into a cloth.

Formulation Example 6. Tablet-type health functional food

Octacosanol powder 15% by weight, lactose hydrolyzate powder 15% by weight, isolated soy protein powder 15% by weight, chitooligosaccharide 15% by weight yeast extract powder 10% by weight, vitamin mineral mixture 10% by weight, magnesium stearate 4.6% by weight, titanium dioxide 0.2% by weight, and 0.2% by weight of glycerin fatty acid ester and 20% by weight of the green younggeum extract of the present invention are blended to prepare a tablet-type health functional food by a conventional method.

Formulation Example 7. Healthy Beverage

5% by weight of honey, 3% by weight of fructose, 0.0001% by weight of sodium riboflavin hydrochloride, 0.0001% by weight of pyridoxine hydrochloride, 86.9998% by weight of water, and 5% by weight of the green young gold extract of the present invention are mixed to prepare a health drink by a conventional method.

Claims (10)

Nokyeonggeum ( Senecio Rowleyanus Jacob ) A pharmaceutical composition for the prevention or treatment of melanoma comprising a water extract as an active ingredient.
The pharmaceutical composition for preventing or treating melanoma according to claim 1, wherein the water extract of Nokyeonggeum is obtained by extracting at least one selected from the group consisting of leaves, stems and roots of Nogyeonggeum.
delete The pharmaceutical composition for preventing or treating melanoma according to claim 1, wherein the water extract of Nogyeonggeum selectively exhibits a proliferation inhibitory effect on melanoma cells.
The pharmaceutical composition for preventing or treating melanoma according to claim 1, wherein the water extract of Nogyeonggeum exhibits antioxidant activity.
The method of claim 1, wherein the water extract of Nogyeonggeum regulates the citric acid cycle of at least one selected from the group consisting of IDH3 (Isocitrate dehydrogenase regulatory subunit 3), SUCLG1 (Succinate--CoA ligase subunit alpha), and MDH1 (Malate Dehydrogenase 1). To inhibit the expression of the gene, melanoma prevention or treatment pharmaceutical composition.
The pharmaceutical composition for preventing or treating melanoma according to claim 1, wherein the water extract of Nogyeonggeum increases the expression of BAX (BCL2-associated X protein gene) gene.
The pharmaceutical composition for preventing or treating melanoma according to claim 1, wherein the nokyeonggeum water extract reduces the expression of a cell death inhibitory gene, and the cell death inhibitory gene is BCL2 (B-cell lymphoma 2).
delete Nokyounggeum ( Senecio Rowleyanus Jacob ) a health functional food composition for preventing or improving melanoma containing water extract as an active ingredient.

Images